

=> fil ref

'REF' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'HOME'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:44:21 ON 20 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 NOV 2005 HIGHEST RN 868522-82-1

DICTIONARY FILE UPDATES: 18 NOV 2005 HIGHEST RN 868522-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10782285AmendBroad.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

1-6 2-12 12-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 12-13

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom

Generic attributes :

12:

Saturation : Saturated

13:


Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:44:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8392 TO ITERATE

23.8% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 162349 TO 173331
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:44:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 166305 TO ITERATE

100.0% PROCESSED 166305 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.03

L3 25 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'HCAPLUS' ENTERED AT 10:44:54 ON 20 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 18 Nov 2005 (20051118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3

L4 4 L3

Ngrazier 10782285Amend

=> d ed abs ibib hitstr 1-4

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 Entered STN: 02 Sep 2005
 G1




AB The title compds. I [Het = 2-pyridinyl or 2-pyrimidinyl; R1 = H, alkyl or a nitrogen-containing heterocyclic ring having 5-6 ring atoms; R2 = H, benzyl or alkyl; and R3 = H, Me, OMe or Cl], useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), stillbirths, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, were prepared. Thus, heating 2-[4-(5-methyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine (preparation given) with 2-ethylphenylamine in the presence of MgCl2 in a sealed vessel at 150°C for 18 h afforded I [Het = 2-pyrimidinyl; R1 = H; R2 = Et; R3 = H]. All the exemplified compds. I showed a Ki of less than 400 nM when tested in screen 1.0 (VIA filter binding assay).


ACCESSION NUMBER: 2005:962050 HCAPLUS
 DOCUMENT NUMBER: 143:266931
 TITLE: Preparation of triazoles which inhibit vasopressin antagonistic activity
 INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079808	A1	20050901	WO 2005-1B79	20050111
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				


L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 863780-55-6 HCAPLUS
 CN Morpholine, 4-[4-phenyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl- (9CI) (CA INDEX NAME)



RN 863780-56-7 HCAPLUS
 CN Pyrimidine, 2-[4-(5-butyl-4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-57-8 HCAPLUS
 CN Pyrimidine, 2-[4-[4-phenyl-5-(1-piperidinylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-58-9 HCAPLUS
 CN Pyrimidine, 2-[4-(5-methyl-4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GV, HL, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: GB 2004-1384 A 20040122
 US 2004-549407P P 20040301

OTHER SOURCE(S): MARPAT 143:266931


IT 863780-52-3P 863780-53-4P 863780-54-5P
 863780-55-6P 863780-56-7P 863780-57-8P
 863780-58-9P 863780-59-0P 863780-60-3P
 863780-61-4P 863780-62-5P 863780-63-6P
 863780-64-7P 863780-65-8P 863780-66-9P
 863780-68-1P 863780-69-2P 863780-71-6P
 863780-72-7P 863780-73-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazoles which inhibit vasopressin antagonistic activity)
 RN 863780-52-3 HCAPLUS
 CN Pyrimidine, 2-[4-[4-(2-ethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-53-4 HCAPLUS
 CN Pyrimidine, 2-[4-[4-(2-propylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-54-5 HCAPLUS
 CN Pyrimidine, 2-[4-[5-methyl-4-[2-(1-methylethyl)phenyl]-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 863780-59-0 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-methoxy-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-60-3 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-chloro-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-61-4 HCAPLUS
 CN Pyridine, 2-[4-[5-methyl-4-(2-methylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 863780-62-5 HCAPLUS
 Pyridine, 2-[4-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-63-6 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-methoxyphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-64-7 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-methoxyphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-65-8 HCAPLUS
 CN Pyridine, 2-[4-[4-(2-methylphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Pyridine, 2-[4-[4-(2,4-dimethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-72-7 HCAPLUS
 CN Pyridine, 2-[4-[4-(2,4-dimethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-73-8 HCAPLUS
 CN Morpholine, 4-[4-[4-(4-chloro-2-methylphenyl)-5-[1-(2-pyridinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 863780-66-9 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-chloro-2-methylphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-68-1 HCAPLUS
 CN Pyridine, 2-[4-[4-phenyl-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-69-2 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-chlorophenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-71-6 HCAPLUS

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 07 Oct 2004
 GI




AB The title compds. I [Q = CH, N; R = (un)substituted alkyl; A represents piperazine ring or piperidine ring; each X = alkyl, optionally partially hydrogenated aryl ring, indan ring or the like; m = 1-3; each Y = halo, OH, CN, alkyl or the like; n = 0-8; when X and Y or two Y groups are attached to the same carbon atom, they may combine to each other to form a C2-C6 alkylene group; and their salts] having tau protein kinase 1 inhibitory and therefore useful for preventive and/or therapeutic treatment of diseases such as neurodegenerative diseases (e.g., Alzheimer disease), were prepared and formulated. E.g., a multi-step synthesis of II.2HCl (starting from 2-bromo-5-fluoroanisole), was given. The biol. data (IC50 values against P-GS1 phosphorylation by bovine cerebral TPK1) were given for representative compds. I.

ACCESSION NUMBER: 2004:817871 HCAPLUS
 DOCUMENT NUMBER: 141:332207
 TITLE: Preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors
 INVENTOR(S): Watanabe, Kazutoshi; Uehara, Fumaki; Hiki, Shinsuke; Yokoshima, Satoshi; Usui, Yoshihiro; Okuyama, Masahiro; Shoda, Aya; Arimoto, Keiichi; Kohara, Toshiyuki; Fukunaga, Kenji
 PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo
 SOURCE: PCT Int. Appl., 433 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004/085408	A1	20041007	WO 2004-JP4320	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN,				

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 TD, TG
 PRIORITY APPLN. INFO.: JP 2003-126021 A 20030326
 JP 2003-126022 A 20030326
 OTHER SOURCE(S): MARPAT 141:332207
 IT 769942-96-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors for treatment and/or prevention of neurodegenerative diseases)
 RN 769942-96-3 HCAPLUS
 CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 02 Sep 2004
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein V = -(CH₂)₀₋₆, -CO-, -CH(alkyl)-; W = O, S(=O)₂, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF₃, OCF₃, alkoxy, Z = -(CH₂)₀₋₆, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2 and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor VIa antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminooxadiazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K_i = 0.24 nM in a VIa filter binding assay.
 ACCESSION NUMBER: 2004:718543 HCAPLUS
 DOCUMENT NUMBER: 141:225517
 TITLE: Preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea
 INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl. 164 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074291	A1	20040902	WO 2004-18432	20040209
V: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LC, LK, LA, LS, LT, LU, LV, MA, MD, MD, MG, HK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516557	AA	20040902	CA 2004-2516557	20040209
US 2004186091	A1	20040923	US 2004-782285	20040218
NL 1025527	A1	20040823	NL 2004-1025527	20040219
NL 1025527	C2	20050314		
US 2005026810	A1	20050203	US 2004-895630	20040720
PRIORITY APPLN. INFO.: GB 2003-3852 A 20030219 GB 2003-17227 A 20030723 US 2003-455455P P 20030318				

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 US 2003-493823P P 20030808
 WO 2004-18432 W 20040209
 OTHER SOURCE(S): MARPAT 141:225517
 IT 748806-15-7P, [4-Chloro-2-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl]methyl]methylamino]ethyl]phenyl]amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea)
 RN 748806-15-7 HCAPLUS
 CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 27 Aug 2002
 AB Homobinuclear [Cl₂M(R₂C:CR₂)MCl₂] [M = Ni(II), Pd(II) or Pt(II) and R-H = 5-phenyl-1,3,4-oxadiazole-2-thiol; 4,5-diphenyl-1,2,4-triazole-3-thiol or mercaptobenzothiazole], were prepared by the reaction of newly prepared S-containing ligands R₂C:CR₂ with the appropriate metal salts of Ni(II), Pd(II) or Pt(II). The complexes were characterized from their CHN elemental anal., molar conductivity, room temperature magnetic moment, IR and electronic spectra. Octahedral environment around Ni(II) and square-planar geometry around Pd(II) or Pt(II) were deduced from magnetic and spectral studies.
 ACCESSION NUMBER: 2002:646439 HCAPLUS
 DOCUMENT NUMBER: 137:379230
 TITLE: Homobinuclear complexes of platinum(II) group metals with sulphur containing ligands R₂C:CR₂ (R-H = 5-phenyl-1,3,4-oxadiazole-2-thiol; 4,5-diphenyl-1,2,4-triazole-3-thiol or mercaptobenzothiazole)
 AUTHOR(S): Al-Hayaly, Lama'an J.; Buttrus, Nabeel H.; Al-Allaf, Talal A. K.
 CORPORATE SOURCE: Department of Chemistry, Faculty Basic Sciences, Applied Science University, Amman, 11931, Jordan
 SOURCE: Asian Journal of Chemistry (2002), 14(3-4), 1421-1426
 CODEN: AJCHEW; ISSN: 0970-7077
 PUBLISHER: Asian Journal of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:379230
 IT 475084-64-1P 475084-65-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 475084-64-1 HCAPLUS
 CN Palladium, tetrachloro[μ-[3,3',3'',3'''-[1,2-ethenediylidene]tetrakis(thio-κS)]tetrakis[4,5-diphenyl-4H-1,2,4-triazole]]di- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 475084-65-2 HCAPLUS
CN Platinum, tetrachloro[μ-[3,3',3'',3'''-(1,2-ethenediylidene)tetrakis(thio-κS)]tetrakis[4,5-diphenyl-4H-1,2,4-triazole]]di- (9Cl) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.21

183.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.92

-2.92

STN INTERNATIONAL LOGOFF AT 10:45:13 ON 20 NOV 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
 STN AnaVist, now available
 NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
 NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
 NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
 NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
 NEWS 8 OCT 03 MATHDI removed from STN
 NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
 to core patent offices
 NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
 NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005
 NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
 of CAPLUS documents for use in third-party analysis and
 visualization tools
 NEWS 13 OCT 27 Free KWIC format extended in full-text databases
 NEWS 14 OCT 27 DIOGENES content streamlined
 NEWS 15 OCT 27 EPFULL enhanced with additional content
 NEWS 16 NOV 14 CA/CAPLUS - Expanded coverage of German academic research

NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
 V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:56:21 ON 20 NOV 2005

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:56:41 ON 20 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 NOV 2005 HIGHEST RN 868522-82-1

DICTIONARY FILE UPDATES: 18 NOV 2005 HIGHEST RN 868522-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10782285broader.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 18 19

chain bonds :

2-12 12-13

ring bonds :

1-2 1-5 1-6 2-3 3-4 4-5 5-14 6-7 6-11 7-8 7-19 8-9 9-10 10-11 14-15 15-16 16-18 18-19

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 5-14 7-19 12-13 14-15 15-16 16-18 18-19

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:Atom 19:Atom

Generic attributes :

12:

Saturation : Saturated

13:


Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR





G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10782285Spec.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16

chain bonds :

2-12 12-13

ring bonds :

1-2 1-5 1-6 2-3 3-4 4-5 5-14 6-7 6-11 7-8 7-16 8-9 9-10 10-11 14-15 15-16

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 5-14 7-16 12-13 14-15 15-16

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

Generic attributes :

12:

Saturation : Saturated

13:


Saturation : Unsaturated

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS



L2 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10782285VCh2OZCh2.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 18

chain bonds :

2-12 12-13

ring bonds :

1-2 1-5 1-6 2-3 3-4 4-5 5-14 6-7 6-11 7-8 7-18 8-9 9-10 10-11 14-15 15-16 16-18

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 5-14 7-18 12-13 14-15 15-16 16-18

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:Atom

Generic attributes :

12:

Saturation : Saturated

13:


Saturation : Unsaturated

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR





G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10782285VandZCH2.str



chain nodes :

```

12 13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 14 15 17
chain bonds :
2-12 12-13
ring bonds :
1-2 1-5 1-6 2-3 3-4 4-5 5-14 6-7 6-11 7-8 7-17 8-9 9-10 10-11 14-15 15-17
exact/norm bonds :
1-2 1-5 1-6 2-3 2-12 3-4 4-5 5-14 7-17 12-13 14-15 15-17
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11

```

G1:O,S,N

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 17:Atom
Generic attributes :
12:
Saturation           : Saturated
13:
Saturation           : Unsaturated


```

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR





G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10782285Vch2.str



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 17 18

chain bonds :

2-12 12-13

ring bonds :

1-2 1-5 1-6 2-3 3-4 4-5 5-14 6-7 6-11 7-8 7-18 8-9 9-10 10-11 14-15 15-17 17-18

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 5-14 7-18 12-13 14-15 15-17 17-18

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 18:Atom

Generic attributes :

12:

Saturation : Saturated

13:


Saturation : Unsaturated

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:04:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 11:04:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L1

=> s 12

SAMPLE SEARCH INITIATED 11:04:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 315 TO ITERATE

100.0% PROCESSED 315 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5236 TO 7364
PROJECTED ANSWERS: 6 TO 266

L8 6 SEA SSS SAM L2

=> s 12 full

FULL SEARCH INITIATED 11:04:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6222 TO ITERATE

100.0% PROCESSED 6222 ITERATIONS 116 ANSWERS
SEARCH TIME: 00.00.01

L9 116 SEA SSS FUL L2

=> s 13

SAMPLE SEARCH INITIATED 11:05:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L3

=> s 13 full

FULL SEARCH INITIATED 11:05:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 110 TO ITERATE

100.0% PROCESSED 110 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L3

=> s 14

SAMPLE SEARCH INITIATED 11:05:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 737 TO ITERATE

100.0% PROCESSED 737 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 13112 TO 16368
PROJECTED ANSWERS: 9 TO 360

L12 9 SEA SSS SAM L4

=> s 14 full

FULL SEARCH INITIATED 11:05:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 14964 TO ITERATE

100.0% PROCESSED 14964 ITERATIONS 142 ANSWERS
SEARCH TIME: 00.00.01

L13 142 SEA SSS FUL L4

=> s 15

SAMPLE SEARCH INITIATED 11:05:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 200 TO 800
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L5

=> s 15 full

FULL SEARCH INITIATED 11:05:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 443 TO ITERATE

100.0% PROCESSED 443 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L15 1 SEA SSS FUL L5

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	810.95	811.16

FILE 'HCAPLUS' ENTERED AT 11:05:57 ON 20 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 18 Nov 2005 (20051118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 115

L16 1 L15

=> d ed abs ibib hitstr

L16 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein V = -(CH₂)_d(O)_e-, -CO-, -CH(alkyl)-; W = O, S(=O)_a, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF₃, OCF₃, alkoxy, Z = -(CH₂)_f(O)_g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminoimidazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K_i = 0.24 nM in a V1a filter binding assay.

ACCESSION NUMBER: 2004:718543 HCAPLUS
DOCUMENT NUMBER: 141:225517
TITLE: Preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea
INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 164 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074291	A1	20040902	WO 2004-18432	20040209
V: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LC, LR, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516557	AA	20040902	CA 2004-2516557	20040209
US 2004186091	A1	20040923	US 2004-782285	20040218
NL 1025527	A1	20040823	NL 2004-1025527	20040219
NL 1025527	C2	20050314		
US 2005026810	A1	20050203	US 2004-895630	20040720
PRIORITY APPLN. INFO.:				
			GB 2003-3852	A 20030219
			GB 2003-17227	A 20030723
			US 2003-455455P	P 20030318

L16 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 2003-493823P P 20030808
WO 2004-18432 W 20040209

OTHER SOURCE(S): MARPAT 141:225517
IT 748805-65-4P, 10-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-6,7-dihydro-4H-5,8-dioxo-2,3,12b-triazabenz[a]cyclopenta[c]cyclonene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Via receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
RN 748805-65-4 HCAPLUS
CN 4H-[1,2,4]Triazolo[3,4-f][1,4,7]benzodioxazone, 10-chloro-6,7-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s 19 and 113
      3 L9
      3 L13
L17      3 L9 AND L13
```

=> remove dup

DUP IS NOT VALID HERE

The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

DELETE BIO?/Q	- delete query names starting with BIO
DELETE ?DRUG/A	- delete answer set names ending with DRUG
DELETE ?ELEC?/L	- delete L-number lists containing ELEC
DELETE ANTICOAG/S	- delete SDI request
DELETE ENZYME/B	- delete batch request
DELETE .MYCLUSTER	- delete user-defined cluster
DELETE .MYFORMAT	- delete user-defined display format
DELETE .MYFIELD	- delete user-defined search field
DELETE NAMELIST MYLIST	- delete mailing list

To delete an ordered document or an offline print, enter its number.

Examples:

DELETE P123001C	- delete print request
DELETE D134002C	- delete document order request

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

DELETE L21	- delete a single L-number
DELETE L3-L6	- delete a range of L-numbers
DELETE LAST 4	- delete the last 4 L-numbers
DELETE L33-	- delete L33 and any higher L-number
DELETE -L55	- delete L55 and any lower L-number
DELETE L2-L6 RENUMBER	- delete a range of L-numbers and renumber remaining L-numbers
DELETE RENUMBER	- renumber L-numbers after deletion of intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

DELETE SAVED/Q	- delete all saved queries
DELETE SAVED/A	- delete all saved answer sets

DELETE SAVED/L - delete all saved L-number lists
DELETE SAVED - delete all saved queries, answer sets,
and L-number lists
DELETE SAVED/S - delete all SDI requests
DELETE SAVED/B - delete all batch requests
DELETE CLUSTER - delete all user-defined clusters
DELETE FORMAT - delete all user-defined display formats
DELETE FIELD - delete all user-defined search fields
DELETE SELECT - delete all E-numbers
DELETE HISTORY - delete all L-numbers and restart the
session at L1

To delete an entire multifile SDI request, enter DELETE and
the name of the request. To delete a component from the
multifile SDI, enter DELETE and the name of the component.

=> s s l9

MISSING OPERATOR S L9

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l9

L18 3 L9

=> d ed abs ibib hitstr 1-3

L18 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 09 May 2005

AB The invention describes the use of a combination of (A) a vasopressin receptor family antagonist, or a pharmaceutically acceptable derivative thereof; and (B) a COX inhibitor, or a pharmaceutically acceptable derivative thereof, for the treatment or prophylaxis of dysmenorrhea. Preparation of celecoxib is also described.

ACCESSION NUMBER: 2005:395085 HCAPLUS

DOCUMENT NUMBER: 142:423900

TITLE: Combinations of cyclooxygenase (COX) inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea

INVENTOR(S): Barker, Laura Daisy; Russell, Rachel Jane; Van der Graaf, Pieter Hadevijn; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039565	A1	20050506	WO 2004-1B3386	20041014
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RD, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: GB 2003-25021 A 20031027

IT 748806-39-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(cyclooxygenase inhibitor-vasopressin receptor antagonist combination for treatment of dysmenorrhea)

RN 748806-39-5 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

Assignee
Noted.
after USFI

NO US App!

L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 17 Dec 2004

AB Use of a phosphodiesterase inhibitor and a vasopressin antagonist in the manufacture of a medicament for the treatment of dysmenorrhea is claimed. Thus, a solution of 4-chloro-2-[[[5-(3,4,5,6-tetrahydro-2H-[1,2,4]bipyridin-4-yl)-1-(1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenylamine (preparation given) was heated with toluene-4-sulfonic acid at 140° for 18 h to give cyclization product, which in CH₂Cl₂ was treated with aqueous H₂CO and then with Na(ACD)3BH to give 8-chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2]bipyridin-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride. A synergistic effect of a PDE5 inhibitor and a V1A antagonist on AVP induced and basal contractile tone in human myometrium was demonstrated.

ACCESSION NUMBER: 2004:1080801 HCAPLUS

DOCUMENT NUMBER: 142:56371

TITLE: Therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea

INVENTOR(S): Bictash, Magda Nabil; Russell, Rachel Jane; Van der Graaf, Pieter Hadevijn; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108138	A1	20041216	WO 2004-1B1848	20040601
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RD, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: US 2005049255 A1 20050303 US 2004-865194 A 20040610

GB 2003-13363 A 20030610

US 2003-484266P P 20030630

IT 748804-63-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)

RN 748804-63-9 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 748806-39-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)

RN 748806-39-5 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT 748804-64-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vasopressin receptor antagonist; therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)

RN 748804-64-0 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L18 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 3 HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Sep 2004
GI

April

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein V = -(CH₂)d(O)e-, -CO-, -CH(alkyl)-; W = O, S(O), NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF₃, OCF₃, alkoxy, Z = -(CH₂)f(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor VIa antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminooxadiazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K_i = 0.24 nM in a *Via* filter binding assay.


ACCESSION NUMBER: 2004:718543 HCAPLUS
DOCUMENT NUMBER: 141:225517
TITLE: Preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea
INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074291	A1	20040902	WO 2004-18432	20040209
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LX, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BV, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2516557	AA	20040902	CA 2004-2516557	20040209
US 2004186091	A1	20040923	US 2004-186091	20040218
NL 1025527	A1	20040923	NL 1025527	20040219
NL 1025527	C2	20050314		
US 2005026810	A1	20050203	US 2004-895630	20040720
PRIORITY APPL. INFO.:			GB 2003-3852	A 20030219
			GB 2003-17227	A 20030723
			US 2003-455455P	P 20030318

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 2003-493823P P 20030808
WO 2004-18432 W 20040209


OTHER SOURCE(S): MARPAT 141:225517
IT 748805-32-SP 748805-33-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Via receptor antagonist: preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea)
RN 748805-32-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).




RN 748805-33-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




IT 748804-60-6P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-63-9P
748804-71-9P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-98-0P,
2-Chloro-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl)ethanone 748805-02-9P
748805-09-6P, 8-Chloro-5-[(pyrrolidin-2-yl)methyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-13-2P 748805-14-3P,
5-(Azetidin-3-yl)-8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-15-4P
8-Chloro-5-(pyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene
748805-20-1P 748806-39-5P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Via receptor antagonist: prepn. of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea)
RN 748804-60-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-63-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-71-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-98-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(chloroacetyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.



RN 748805-13-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-morpholinylmethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-02-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2S)-2-pyrrolidinylcarbonyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl


RN 748805-09-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 748805-14-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-(3-azetidyl)-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-15-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 748805-20-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5-(6H)-carboxamide, 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748806-39-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 748804-61-7P, 5-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene
748804-62-8P, 1-[1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethanone 748804-64-0P
8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride
748804-65-1P, 8-Chloro-5-isopropyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748804-66-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5-(tetrahydropyran-4-yl)-5,6-dihydro-4H-2,3,5,10b-

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

748805-41-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl] (tetrahydropyran-4-yl)methanone 748805-42-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl] [1-(methyl)piperidin-4-yl]methanone 748805-43-8P, 8-Chloro-5-(1-methylazetidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-44-9P 748805-45-0P 748805-46-1P
748805-47-2P 748805-48-3P, 8-Chloro-5-(1-methylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-49-4P, 8-Chloro-5-(1-isopropylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-50-7P, 2-[8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethanol 748805-51-8P, 8-Chloro-5-(2-methoxyethyl)-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-52-9P, 8-Chloro-5-(pyrimidin-2-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-53-0P, 8-Chloro-5-(pyrimidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-54-1P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-carboxaldehyde 748805-55-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-56-3P, 8-Chloro-5-[(pyridin-2-yl)methyl]-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-57-4P 748805-58-5P
748805-59-6P, 8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-60-9P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4,5-dihydro-2,3,5,10b-tetraazabenz[e]azulene-6-one 748805-63-2P, 8-Chloro-5,6-dimethyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Via receptor antagonist; prepn. of triazoles as vasopressin receptor
Via antagonists for treating of dysmenorrhea)

RN 748804-61-7 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

tetraazabenz[e]azulene 748804-67-3P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethanone dihydrochloride 748804-68-4P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]cyclopropylmethanone dihydrochloride 748804-69-5P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]-2,2-dimethylpropan-1-one dihydrochloride 748804-70-8P, 8-Chloro-5-methanesulfonyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-72-0P, 8-Chloro-5-methyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-73-1P, 8-Chloro-5-isopropyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-74-2P, 8-Chloro-5-methanesulfonyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-75-3P, [8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]cyclopropylmethanone 748804-76-4P, 1-[8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]-2,2-dimethylpropan-1-one 748804-77-5P, 1-[8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethanone 748804-78-1P, 2-(Azetidin-1-yl)-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethanone 748805-00-7P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl] (pyrrolidin-1-yl)ethanone 748805-01-8P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]pyrrolidin-3-ylmethanone trihydrochloride 748805-03-0P 748805-04-1P 748805-05-2P
748805-06-3P 748805-07-4P 748805-08-5P
748805-10-9P 748805-11-0P 748805-12-1P
748805-16-5P, 8-Chloro-5-(piperidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-17-6P, 8-Chloro-5-[1,4]oxazepan-6-yl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-18-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]morpholin-4-ylmethanone 748805-19-8P
748805-21-2P 748805-22-3P 748805-23-4P, [2-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethyl]dimethylamine trihydrochloride 748805-24-5P, 8-Chloro-5-[2-(pyrrolidin-1-yl)ethyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-25-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]acetic acid methyl ester 748805-26-7P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]-3-methoxypropan-1-one 748805-27-8P 748805-28-9P, 8-Chloro-5-(1-methylpyrrolidin-2-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-29-0P 748805-30-3P
748805-31-4P 748805-34-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl] (2S)-1-methylpyrrolidin-2-yl)methanone 748805-35-8P 748805-36-9P 748805-37-0P
748805-38-1P 748805-39-2P 748805-40-5P

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-62-8 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-64-0 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-65-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methylethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 748804-66-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-67-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 748804-68-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(cyclopropylcarbonyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-69-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(2,2-dimethyl-1-oxopropyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 748804-70-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-72-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-73-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methylethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-74-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-75-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(cyclopropylcarbonyl)-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-99-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-(1-azetidinylacetyl)-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-00-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-76-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(2,2-dimethyl-1-oxopropyl)-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748804-77-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-01-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(3-pyrrolidinylcarbonyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 3 HCl

RN 748805-03-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2R)-2-pyrrolidinylcarbonyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A



● 3 HCl

RN 748805-05-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 748805-06-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-piperidinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



Absolute stereochemistry.



● 3 HCl

RN 748805-04-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-piperidinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



● 3 HCl

RN 748805-07-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-morpholinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●3 HCl

RN 748805-08-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-morpholinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●3 HCl


RN 748805-10-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 748805-11-0 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748805-12-1 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-piperidinylmethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 748805-16-5 HCAPLUS



●3 HCl

RN 748805-17-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(hexahydro-1,4-oxazepin-6-yl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-18-7 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(4-morpholinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

540/544

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-19-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxylic acid,
 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX
 NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-21-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-
 pyridinyl)-4-piperidinyl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX
 NAME)

PAGE 1-A




L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A




RN 748805-22-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-
 methyl-1-piperazinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 748805-23-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-ethanamine,
 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride
 (9CI) (CA INDEX NAME)


L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 3 HCl

RN 748805-24-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-
 pyridinyl)-4-piperidinyl]-5-[2-(1-pyrrolidinyl)ethyl]-, trihydrochloride
 (9CI) (CA INDEX NAME)


PAGE 1-A






● 3 HCl


RN 748805-25-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-acetic acid, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 748805-26-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(3-methoxy-1-oxopropyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-] (9CI) (CA INDEX NAME)




RN 748805-27-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-[(3-(dimethylamino)-1-oxopropyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-] (9CI) (CA INDEX NAME)



RN 748805-28-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-1-methyl-2-pyrrolidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl


RN 748805-29-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-(2S)-1-methyl-2-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 748805-30-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-(2R)-1-methyl-2-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748805-31-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-(2S)-1-methyl-2-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



●3 HCl

RN 748805-34-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-
 [(2S)-1-methyl-2-pyrrolidinyl]carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-35-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-
 [(2R)-1-methyl-2-pyrrolidinyl]carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-36-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-
 methyl-3-pyrrolidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 748805-37-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-
 [(2R)-1-methyl-2-piperidinyl]carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-
 , trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 748805-38-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-
 methyl-3-piperidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-39-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-
 methyl-2-morpholinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-40-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-3-morpholinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-41-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[(2-pyridinyl)-4-piperidinyl]-5-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (9CI)
 (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-42-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-4-piperidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-43-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-azetidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-44-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(1-methylethyl)-3-azetidiny]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-45-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(1-methyl-4-piperidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Et

RN 748805-47-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(1-methylethyl)-4-piperidinyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Me

RN 748805-46-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(1-ethyl-4-piperidinyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

i-Pr

RN 748805-48-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-methyl-3-pyrrolidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Me

RN 748805-49-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(1-methylethyl)-3-pyrrolidinyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

i-Pr


● 3 HCl

RN 748805-50-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-ethanol, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-51-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-methoxyethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-52-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-53-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 748805-54-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxaldehyde, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-55-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide,
 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX
 NAME)



RN 748805-56-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-
 pyridinylmethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX
 NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-58-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1H-
 pyrazol-3-ylmethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX
 NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-57-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-
 pyrimidinyl)-4-piperidinyl]-5-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-59-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide,
 8-chloro-N,N-dimethyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA
 INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-60-9 HCAPLUS
 CN 6H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepin-6-one, 8-chloro-4,5-dihydro-5-methyl-1-[(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-63-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5,6-dimethyl-1-[(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 748806-17-9 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[8-chloro-1-[(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 748806-18-0 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[8-chloro-1-[(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748806-19-1 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[8-chloro-1-[(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 748804-97-9P, 1-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-dimethylaminoethanone 748806-17-9P 748806-18-0P 748806-19-1P 748806-20-4P 748806-21-5P 748806-22-6P 748806-23-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (intermediate, V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748804-97-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-[(dimethylamino)acetyl]-5,6-dihydro-1-[(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-20-4 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 2-[[[8-chloro-1-[(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748806-21-5 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 748806-22-6 HCAPLUS
 CN 4-Morpholinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




IT 748806-16-8P, tert-Butyl 3-[[8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]carbonyl]pyrrolidine-1-carboxylate 748806-24-8P
 3-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]azetidine-1-carboxylic acid tert-butyl ester 748806-25-9P, 3-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 748806-26-0P, 4-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]piperidine-1-carboxylic acid tert-butyl ester 748806-27-1P, 6-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-10b-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-[1,4]oxazepan-4-carboxylic acid 748806-40-8P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene dibesylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Intermediate: preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)
 RN 748806-16-8 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Page 4020/11/2005

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748806-23-7 HCAPLUS
 CN 4-Morpholinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-24-8 HCAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-25-9 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-26-0 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-27-1 HCAPLUS
 CN 1,4-Oxazepine-4(5H)-carboxylic acid, 6-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748806-40-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, dibenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 748806-39-5
 CHF C21 H23 Cl N6



CH 2
 CRN 98-11-3
 CIP C6 H6 O3 S



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10782285Amend

=> s l13

L19 3 L13

=> d ed abs ibib hitstr 1-3

*L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 09 May 2005

AB The invention describes the use of a combination of (A) a vasopressin receptor family antagonist, or a pharmaceutically acceptable derivative thereof; and (B) a COX inhibitor, or a pharmaceutically acceptable derivative thereof, for the treatment or prophylaxis of dysmenorrhea. Preparation of celecoxib is also described.

ACCESSION NUMBER: 2005:395085 HCAPLUS

DOCUMENT NUMBER: 142:423900

TITLE: Combinations of cyclooxygenase (COX) inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea

INVENTOR(S): Barker, Laura Daisy; Russell, Rachel Jane; Van der Graaf, Pieter Hadevijn; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039565	A1	20050506	WO 2004-1B3386	20041014
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, HL, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2003-25021 A 20031027


IT

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase inhibitor-vasopressin receptor antagonist combination for treatment of dysmenorrhea)

RN 748806-39-5 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 17 Dec 2004

AB Use of a phosphodiesterase inhibitor and a vasopressin antagonist in the manufacture of a medicament for the treatment of dysmenorrhea is claimed. Thus, a solution of 4-chloro-2-[[[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]amino]methyl]phenylamine (preparation given) was heated with toluene-4-sulfonic acid at 140° for 18 h to give cyclization product, which in CH2Cl2 was treated with aqueous H2CO and then with Na(AcO)3BH to give 8-chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride. A synergistic effect of a PDE5 inhibitor and a V1A antagonist on AVP induced and basal contractile tone in human myometrium was demonstrated.

ACCESSION NUMBER: 2004:1080801 HCAPLUS

DOCUMENT NUMBER: 142:56371

TITLE: Therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea

INVENTOR(S): Bictash, Magda Nabil; Russell, Rachel Jane; Van der Graaf, Pieter Hadevijn; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108138	A1	20041216	WO 2004-1B1848	20040601
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, HL, MR, NE, SN, TD, TG			

US 2005049255 A1 20050303 US 2004-865194 20040610

PRIORITY APPLN. INFO.: GB 2003-12363 A 20030610

US 2003-484266P P 20030630

IT 748804-63-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)

RN 748804-63-9 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 748806-39-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)

RN 748806-39-5 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 748804-64-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(vasopressin receptor antagonist; therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)

RN 748804-64-0 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 3 HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein V = -(CH₂)d(O)e-, -CO-, -CH(alkyl)-; W = O, S(=O)a, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF₃, OCF₃, alkoxy, Z = -(CH₂)f(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor VIa antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminoimidazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K_i = 0.24 nM in a VIa filter binding assay.


ACCESSION NUMBER: 2004:718543 HCAPLUS
DOCUMENT NUMBER: 141:225517
TITLE: Preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea
INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074291	A1	20040902	WO 2004-1B432	20040209
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, A2, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LA, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI, NI				
RW: BV, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516557	AA	20040902	CA 2004-2516557	20040209
US 2004196091	A1	20040923	US 2004-782285	20040218
NL 1025527	A1	20040823	NL 2004-1025527	20040219
NL 1025527	C2	20050314		
US 2005026810	A1	20050203	US 2004-895630	20040720
PRIORITY APPLN. INFO.:			GB 2003-3852	A 20030219
			GB 2003-17227	A 20030723
			US 2003-455455P	P 20030318

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 2003-493823P P 20030808
WO 2004-1B432 W 20040209


OTHER SOURCE(S): MARPAT 141:225517
IT 748805-32-5P 748805-33-6P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Via receptor antagonist; preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea)
RN 748805-32-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, (+)-(9CI) (CA INDEX NAME)

Rotation (-).




RN 748805-33-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




IT 748804-60-6P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-63-9P
748804-71-9P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-79-7P,
4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)-3,4,5,6-

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
tetrahydro-2H-[1,2']bipyridinyl-6'-carbonitrile 748804-98-0P,
2-Chloro-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748805-02-9P
748805-09-6P, 8-Chloro-5-[(pyrrolidin-2-yl)methyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-13-2P 748805-14-3P,
5-(Azetidin-3-yl)-8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-15-4P,
8-Chloro-5-(pyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-20-1P 748805-66-5P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 748806-39-5P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Via receptor antagonist; prepn. of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea)
RN 748804-60-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-63-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-71-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-79-7 HCAPLUS
CN 2-Pyridinecarbonitrile, 6-[4-(8-chloro-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-1-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-98-0 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(chloroacetyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-02-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2S)-2-pyrrolidinylcarbonyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●3 HCl

RN 748805-09-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-13-2 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-morpholinylmethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 748805-14-3 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-(3-azetidiny)-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

RN 748806-39-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

CN1CC2=C(C=C(C=C2N1)C3=CC=CC=C3Cl)C(=N4C=CC=CC4)N5CCN(C5)c6ccccc6


748804-61-7P, 5-Methyl-1-[(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene]
748804-62-8P, 1-[(1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl)ethanone 748804-64-0P
- 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride
748804-65-1P, 8-Chloro-5-isopropyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748804-66-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5-(tetrahydropropan-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-67-3P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone dihydrochloride 748804-68-4P
-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]cyclopropylmethanone dihydrochloride 748804-69-5P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidin-2-ylmethanone dihydrochloride 748804-70-8P
-8-Chloro-5-methanesulfonyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-72-0P
-8-Chloro-5-methyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-73-1P
-8-Chloro-5-isopropyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-74-2P
-8-Chloro-5-methanesulfonyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-75-3P
-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]cyclopropylmethanone 748804-76-4P
1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidin-2-ylmethanone dihydrochloride 748804-77-5P
1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748804-78-6P
-8-Chloro-1-(6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-80-0P
-4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carboxylic acid amide 748804-81-1P
-13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazapentadeca-1(11),3,5,12,14-pentene 748804-82-2P, 1-[13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.0.2]pentadeca-1(11),3,5,12,14-pentaen-8-yl]ethanone 748804-83-3P
1,3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene trihydrochloride 748804-84-0P
9-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-85-7P
1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethoxy-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-86-8P
-8-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-89-1P
1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748804-90-1P
1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-(pyrrolidin-1-yl)ethanone 748805-01-8P
-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidin-3-ylmethanone trihydrochloride 748805-03-0P 748805-04-1P
748805-05-2P 748805-06-3P 748805-07-4P
748805-08-5P 748805-10-9P 748805-11-1P
748805-12-1P 748805-16-5P, 8-Chloro-5-(piperidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-17-6P
-8-Chloro-5-[1,4-oxazepan-6-yl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-18-7P
-8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]morpholin-4-ylmethanone 748805-19-8P 748805-21-2P 748805-22-3P
748805-23-4P, [2-(8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl)ethyl]dimethylamine trihydrochloride 748805-24-5P
-8-Chloro-5-[2-(pyrrolidin-1-yl)ethyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-25-6P
-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]acetic acid methyl ester 748805-26-1P
-8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-3-methoxypropan-1-one 748805-27-8P
748805-28-9P, -8-Chloro-5-(1-methylpyrrolidin-(2S)-2-ylmethyl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-29-0P
748805-30-3P 748805-31-4P 748805-34-7P
748805-35-8P 748805-36-9P 748805-37-0P
748805-38-1P 748805-39-2P 748805-40-3P
748805-41-4P 748805-42-5P 748805-43-6P
748805-44-7P 748805-45-8P 748805-46-9P
748805-47-0P 748805-48-1P 748805-49-2P
748805-50-3P 748805-51-4P 748805-52-5P
748805-53-6P 748805-54-7P 748805-55-8P
748805-56-9P 748805-57-0P 748805-58-1P
748805-59-2P 748805-60-3P 748805-61-4P
748805-62-5P 748805-63-6P 748805-64-7P
748805-65-8P 748805-66-9P 748805-67-0P
748805-68-1P 748805-69-2P 748805-70-3P
748805-71-4P 748805-72-5P 748805-73-6P
748805-74-7P 748805-75-8P 748805-76-9P
748805-77-0P 748805-78-1P 748805-79-2P
748805-80-3P 748805-81-4P 748805-82-5P
748805-83-6P 748805-84-7P 748805-85-8P
748805-86-9P 748805-87-0P 748805-88-1P
748805-89-2P 748805-90-3P 748805-91-4P
748805-92-5P 748805-93-6P 748805-94-7P
748805-95-8P 748805-96-9P 748805-97-0P
748805-98-1P 748805-99-2P 748805-100-3P
748805-101-4P 748805-102-5P

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


748805-38-1P 748805-39-2P 748805-40-5P
 748805-41-6P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]tetrahydropyran-4-yl)methanone 748805-42-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl][1-(methyl)piperidin-4-yl]methanone 748805-43-8P,
 8-Chloro-5-(1-methylazetidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-44-9P 748805-45-0P 748805-46-1P
 748805-47-2P 748805-48-3P, 8-Chloro-5-(1-methylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-49-4P,
 8-Chloro-5-(1-isopropylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-50-7P, 2-[8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-yl]ethanol 748805-51-8P, 8-Chloro-5-(2-methoxyethyl)-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-52-9P, 8-Chloro-5-(pyrimidin-2-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-53-0P, 8-Chloro-5-(pyrimidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-54-1P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-carboxaldehyde 748805-55-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-56-3P, 8-Chloro-5-[(pyridin-2-yl)methyl]-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-57-4P 748805-58-5P
 748805-59-6P, 8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-60-9P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4,5-dihydro-2,3,5,10b-tetraazabenz[e]azulene-6-one 748805-61-0P, 13-Chloro-9-methyl-3-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-2,4,5,9-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748805-62-1P, 13-Chloro-8-methyl-3-(1-(pyrimidin-2-yl)piperidin-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748805-63-2P,
 8-Chloro-5,6-dimethyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-64-3P,
 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethyl-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748805-67-6P,
 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 5-oxide 748805-68-7P,
 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 5,5-dioxide
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Via receptor antagonist; prepn. of triazoles as vasopressin receptor
 Via antagonists for treating of dysmenorrhea)

RN 748804-61-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-62-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-64-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-65-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methylethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 748804-66-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-67-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 748804-68-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(cyclopropylcarbonyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-69-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(2,2-dimethyl-1-oxopropyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 748804-70-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-74-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-75-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(cyclopropylcarbonyl)-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-72-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-73-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methylethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-76-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(2,2-dimethyl-1-oxopropyl)-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-77-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-78-6 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8-chloro-1-[1-(6-(trifluoromethyl)-2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-80-0 HCAPLUS
CN 2-Pyridinecarboxamide, 6-[4-(8-chloro-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-1-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748804-84-4 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazocine, 6,7-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-85-5 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8-chloro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-86-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazocine, 9-chloro-6,7-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748804-81-1 HCAPLUS
CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazocine, 9-chloro-4,5,6,7-tetrahydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-82-2 HCAPLUS
CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazocine, 5-acetyl-9-chloro-4,5,6,7-tetrahydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-83-3 HCAPLUS
CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazocine, 9-chloro-4,5,6,7-tetrahydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-87-7 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazocine, 6,7-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 748804-88-8 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-89-9 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 7-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-90-2 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-91-3 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8-methoxy-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-92-4 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8-fluoro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-93-5 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8,9-difluoro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-94-6 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 9-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-95-7 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 1-[1-(2-pyridinyl)-4-piperidinyl]-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748804-96-8 HCAPLUS
CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 8-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-99-1 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-[1-(azetidinylacetyl)-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-00-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[(2-pyridinyl)-4-piperidinyl]-5-(1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl

RN 748805-04-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylcarbonyl]-1-[(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 748805-01-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[(2-pyridinyl)-4-piperidinyl]-5-(3-pyrrolidinylcarbonyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●3 HCl

RN 748805-03-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[(2-pyridinyl)-4-piperidinyl]-5-[(2R)-2-pyrrolidinylcarbonyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



●3 HCl

RN 748805-05-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylcarbonyl]-1-[(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 748805-06-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-piperidinylcarbonyl]-1-[(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●3 HCl

RN 748805-07-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-morpholinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



●3 HCl


RN 748805-10-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748805-11-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748805-12-1 HCAPLUS

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



●3 HCl


RN 748805-08-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-morpholinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-piperidinylmethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 748805-16-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(4-piperidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-17-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(hexahydro-1,4-oxazepin-6-yl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-18-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(4-morpholinylcarbonyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-21-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(1-methyl-1-piperazinylcarbonyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 748805-19-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxylic acid, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A




RN 748805-22-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(1-methyl-1-piperazinylcarbonyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 748805-23-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-ethanamine, 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-24-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[2-(1-pyrrolidinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-27-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-[3-(dimethylamino)-1-oxopropyl]-6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 748805-28-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-1-methyl-2-pyrrolidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A




RN 748805-25-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-acetic acid, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 748805-26-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(3-methoxy-1-oxopropyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-29-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-1-methyl-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-30-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-1-methyl-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-31-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-36-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 2-A



●3 HCl

RN 748805-34-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748805-35-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 748805-37-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 748805-38-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-39-2 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-40-5 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-3-morpholinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-41-6 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (9CI)
(CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-42-7 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-4-piperidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-43-8 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methyl-3-azetidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-44-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methylethyl)-3-azetidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-45-0 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methyl-4-piperidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-46-1 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(1-ethyl-4-piperidinyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-47-2 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(1-ethyl-4-piperidinyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

i-Pr

RN 748805-48-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(2-pyridinyl)-4-piperidinyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Me

RN 748805-49-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(2-pyridinyl)-4-piperidinyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

i-Pr


● 3 HCl

RN 748805-50-7 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-ethanol, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-51-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-methoxyethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-52-9 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-53-0 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 748805-54-1 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxaldehyde, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-57-4 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]-5-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-55-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide, 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-56-3 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-pyridinylmethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-58-5 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1H-pyrazol-3-ylmethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-59-6 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide,
 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA
 INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-60-9 HCAPLUS
 CN 6H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-6-one, 8-chloro-4,5-dihydro-5-
 methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-61-0 HCAPLUS
 CN [1,2,4]Triazolo[4,3-a][1,5]benzodiazocine, 9-chloro-4,5,6,7-tetrahydro-6-
 methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748805-62-1 HCAPLUS
 CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazocine, 9-chloro-4,5,6,7-tetrahydro-5-
 methyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-63-2 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5,6-
 dimethyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-64-3 HCAPLUS
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazepine, 1-[1-(2-pyridinyl)-4-
 piperidinyl]-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 748805-67-6 HCAPLUS
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzothiazepine, 8-chloro-1-[1-(2-
 pyridinyl)-4-piperidinyl]-, 5-oxide (9CI) (CA INDEX NAME)



RN 748805-68-7 HCAPLUS
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzothiazepine, 8-chloro-1-[1-(2-
 pyridinyl)-4-piperidinyl]-, 5,5-dioxide (9CI) (CA INDEX NAME)


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 748804-97-9P, 1-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-dimethylaminoethanone 748806-17-9P 748806-18-OP
748806-19-1P 748806-20-4P 748806-21-5P
748806-22-6P 748806-23-7P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate, V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748804-97-9 HCAPLUS
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-[(dimethylamino)acetyl]-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 748806-20-4 HCAPLUS
CN 1-Piperidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 748806-17-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 748806-18-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 748806-19-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)-(9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 748806-21-5 HCAPLUS
CN 1-Piperidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748806-22-6 HCAPLUS
CN 4-Morpholinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748806-23-7 HCAPLUS
CN 4-Morpholinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




IT 748806-16-8P, tert-Butyl 3-[[8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]carbonyl]pyrrolidine-1-carboxylate 748806-24-8P, 3-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]azetidine-1-carboxylic acid tert-butyl ester 748806-25-9P, 3-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 748806-26-0P, 4-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]piperidine-1-carboxylic acid tert-butyl ester 748806-27-1P, 6-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-10b-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-[1,4]oxazepan-4-carboxylic acid 748806-40-8P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene dibesylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of triazoles as vasopressin receptor Vla


L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
antagonists for treating of dysmenorrhea)

RN 748806-16-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 748806-24-8 HCAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-25-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-26-0 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748806-27-1 HCAPLUS
 CN 1,4-Oxazepine-4(5H)-carboxylic acid, 6-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 748806-40-8 HCAPLUS
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, dibenzenesulfonate (9CI) (CA INDEX NAME)

CH 1

CRN 748806-39-5
 CHF C21 H23 Cl N6

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 98-11-3
 CHF C6 H6 O3 S



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10782285Amend

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

41.93

853.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY



SESSION

CA SUBSCRIBER PRICE

-5.11

-5.11

STN INTERNATIONAL LOGOFF AT 11:07:49 ON 20 NOV 2005



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

1-6 2-12 12-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 12-13

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom

Generic attributes :

12:

Saturation : Saturated

13:


Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:44:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8392 TO ITERATE

23.8% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 162349 TO 173331
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:44:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 166305 TO ITERATE

100.0% PROCESSED 166305 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.03

L3 25 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'HCAPLUS' ENTERED AT 10:44:54 ON 20 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 18 Nov 2005 (20051118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 4 L3

=> d ed abs ibib hitstr 1-4

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Sep 2005
GI



AB The title compds. I [Het = 2-pyridinyl or 2-pyrimidinyl; R1 = H, alkyl or a nitrogen-containing heterocyclic ring having 5-6 ring atoms; R2 = H, benzyl or alkyl; and R3 = H, Me, OMe or Cl], useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlemerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, were prepared Thus, heating 2-[4-(5-methyl-[1,3,4]oxadiazol-2-yl)piperidin-1-yl]pyrimidine (preparation given) with 2-ethylphenylamine in the presence of MgCl₂ in a sealed vessel at 150°C for 18 h afforded I [Het = 2-pyrimidinyl; R1 = H; R2 = Et; R3 = H]. All the exemplified compds. I showed a K_i of less than 400 nM when tested in screen 1.0 (V1A filter binding assay).

ACCESSION NUMBER: 2005:962050 HCAPLUS
DOCUMENT NUMBER: 143:266931
TITLE: Preparation of triazoles which inhibit vasopressin antagonistic activity
INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079808	A1	20050901	WO 2005-IB79	20050111
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRIORITY APPLN. INFO.:

GB 2004-1384

A 20040122

US 2004-549407P

P 20040301

OTHER SOURCE(S): MARPAT 143:266931


IT 863780-52-3P 863780-53-4P 863780-54-5P
 863780-55-6P 863780-56-7P 863780-57-8P
 863780-58-9P 863780-59-0P 863780-60-3P
 863780-61-4P 863780-62-5P 863780-63-6P
 863780-64-7P 863780-65-8P 863780-66-9P
 863780-68-1P 863780-69-2P 863780-71-6P
 863780-72-7P 863780-73-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of triazoles which inhibit vasopressin antagonistic activity)


RN 863780-52-3 HCAPLUS

CN Pyrimidine, 2-[4-[4-(2-ethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-53-4 HCAPLUS

CN Pyrimidine, 2-[4-[5-methyl-4-(2-propylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-54-5 HCAPLUS


CN Pyrimidine, 2-[4-[5-methyl-4-[2-(1-methylethyl)phenyl]-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-55-6 HCAPLUS
 CN Morpholine, 4-[[4-phenyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 863780-56-7 HCAPLUS
 CN Pyrimidine, 2-[4-(5-butyl-4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-57-8 HCAPLUS
 CN Pyrimidine, 2-[4-[4-phenyl-5-(1-piperidinylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-58-9 HCAPLUS
 CN Pyrimidine, 2-[4-(5-methyl-4-phenyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-59-0 HCAPLUS
CN Pyridine, 2-[4-[4-(4-methoxy-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-60-3 HCAPLUS
CN Pyridine, 2-[4-[4-(4-chloro-2-methylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-61-4 HCAPLUS
CN Pyridine, 2-[4-[5-methyl-4-(2-methylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-62-5 HCAPLUS
CN Pyridine, 2-[4-[4-(4-chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-63-6 HCAPLUS
CN Pyridine, 2-[4-[4-(4-methoxyphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-64-7 HCAPLUS
CN Pyridine, 2-[4-[4-(4-methoxyphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-65-8 HCAPLUS
 CN Pyridine, 2-[4-[4-(2-methylphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-66-9 HCAPLUS
 CN Pyridine, 2-[4-[4-(4-chloro-2-methylphenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-68-1 HCAPLUS
 CN Pyridine, 2-[4-[4-phenyl-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-69-2 HCAPLUS

CN Pyridine, 2-[4-[4-(4-chlorophenyl)-5-(2H-1,2,3-triazol-2-ylmethyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-71-6 HCAPLUS

CN Pyridine, 2-[4-[5-methyl-4-(4-methylphenyl)-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 863780-72-7 HCAPLUS

CN Pyridine, 2-[4-[4-(2,4-dimethylphenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 863780-73-8 HCAPLUS

CN Morpholine, 4-[4-(4-chloro-2-methylphenyl)-5-[1-(2-pyridinyl)-4-piperidinyl]-4H-1,2,4-triazol-3-yl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 07 Oct 2004
 GI



AB The title compds. I [Q = CH, N; R = (un)substituted alkyl; A represents piperazine ring or piperidine ring; each X = alkyl, optionally partially hydrogenated aryl ring, indan ring or the like; m = 1-3; each Y = halo, OH, CN, alkyl or the like; n = 0-8; when X and Y or two Y groups are attached to the same carbon atom, they may combine to each other to form a C2-C6 alkylene group; and their salts] having tau protein kinase 1 inhibitory and therefore useful for preventive and/or therapeutic treatment of diseases such as neurodegenerative diseases (e.g., Alzheimer disease), were prepared and formulated. E.g., a multi-step synthesis of II.2HCl (starting from 2-bromo-5-fluoroanisole), was given. The biol. data (IC50 values against P-GS1 phosphorylation by bovine cerebral TPK1) were given for representative compds. I.

ACCESSION NUMBER: 2004:817871 HCAPLUS
 DOCUMENT NUMBER: 141:332207
 TITLE: Preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1 inhibitors
 INVENTOR(S): Watanabe, Kazutoshi; Uehara, Fumiaki; Hiki, Shinsuke; Yokoshima, Satoshi; Usui, Yoshihiro; Okuyama, Masahiro; Shoda, Aya; Aritomo, Keiichi; Kohara, Toshiyuki; Fukunaga, Kenji
 PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan; Sanofi-Synthelabo
 SOURCE: PCT Int. Appl., 433 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085408	A1	20041007	WO 2004-JP4320	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

PRIORITY APPLN. INFO.:

JP 2003-126021

A 20030326

JP 2003-126022

A 20030326

OTHER SOURCE(S):

MARPAT 141:332207


IT 769942-96-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 2,3,6-trisubstituted-4-pyrimidones as tau protein kinase 1
inhibitors for treatment and/or prevention of neurodegenerative
diseases)

RN 769942-96-3 HCAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[4-(4-phenyl-4H-1,2,4-triazol-3-yl)-1-
piperidinyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein V = -(CH₂)_d(O)e-, -CO-, -CH(alkyl)-; W = O, S(:O)a, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF₃, OCF₃, alkoxy, Z = -(CH₂)_f(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substitued saturated N-containing heterocycle; B = Ph, (un)substitued saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor V1a antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminooxadiazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K_i = 0.24 nM in a V1a filter binding assay.

ACCESSION NUMBER: 2004:718543 HCAPLUS
DOCUMENT NUMBER: 141:225517
TITLE: Preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea
INVENTOR(S): Bryans, Justin Stephen; Johnson, Patrick Stephen; Ryckmans, Thomas; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074291	A1	20040902	WO 2004-IB432	20040209
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516557	AA	20040902	CA 2004-2516557	20040209
US 2004186091	A1	20040923	US 2004-782285	20040218
NL 1025527	A1	20040823	NL 2004-1025527	20040219
NL 1025527	C2	20050314		
US 2005026810	A1	20050203	US 2004-895630	20040720
PRIORITY APPLN. INFO.:			GB 2003-3852	A 20030219
			GB 2003-17227	A 20030723
			US 2003-455455P	P 20030318
			US 2003-493823P	P 20030808
			WO 2004-IB432	W 20040209
OTHER SOURCE(S):	MARPAT 141:225517			
IT 748806-15-7P,	[4-Chloro-2-[1-[[[4-(4-chlorophenyl)-5-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H-[1,2,4]triazol-3-yl)methyl]methylamino]ethyl]pheny			


1]amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748806-15-7 HCAPLUS

CN 4H-1,2,4-Triazole-3-methanamine, N-[1-(2-amino-5-chlorophenyl)ethyl]-4-(4-chlorophenyl)-N-methyl-5-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 27 Aug 2002
 AB Homobinuclear [Cl₂M(R₂C:CR₂)MC₁₂] [M = Ni(II), Pd(II) or Pt(II) and R-H = 5-phenyl-1,3,4-oxadiazole-2-thiol; 4,5-diphenyl-1,2,4-triazole-3-thiol or mercaptobenzothiazole], were prepared by the reaction of newly prepared S-containing ligands R₂C:CR₂ with the appropriate metal salts of Ni(II), Pd(II) or Pt(II). The complexes were characterized from their CHN elemental anal., molar conductivity, room temperature magnetic moment, IR and electronic spectra. Octahedral environment around Ni(II) and square-planar geometry around Pd(II) or Pt(II) were deduced from magnetic and spectral studies.

ACCESSION NUMBER: 2002:646439 HCAPLUS
 DOCUMENT NUMBER: 137:379230
 TITLE: Homobimetallic complexes of platinum(II) group metals with sulphur containing ligands R₂C:CR₂ (R-H = 5-phenyl-1,3,4-oxadiazole-2-thiol; 4,5-diphenyl-1,2,4-triazole-3-thiol or mercaptobenzothiazole)
 AUTHOR(S): Al-Hayaly, Lama'an J.; Buttrus, Nabeel H.; Al-Allaf, Talal A. K.
 CORPORATE SOURCE: Department of Chemistry, Faculty Basic Sciences, Applied Science University, Amman, 11931, Jordan
 SOURCE: Asian Journal of Chemistry (2002), 14(3-4), 1421-1426
 CODEN: AJCHEW; ISSN: 0970-7077
 PUBLISHER: Asian Journal of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:379230
 IT 475084-64-1P 475084-65-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 475084-64-1 HCAPLUS
 CN Palladium, tetrachloro[μ-[3,3',3'',3'''-[1,2-ethenediylidenetetakis(thio-κS)]tetraakis[4,5-diphenyl-4H-1,2,4-triazole]]]di- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 475084-65-2 HCAPLUS
 CN Platinum, tetrachloro[μ-[3,3',3'',3'''-[1,2-ethenediylidenetetrakis(thio-κS)]tetrakis[4,5-diphenyl-4H-1,2,4-triazole]]]di- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10782285

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
22.21	183.75

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.92	-2.92

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:45:13 ON 20 NOV 2005

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	32	"5521173"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/11/20 12:16
L2	2	"5438035"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/11/20 12:55
L3	661	540/544,563,566.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/11/20 12:56
L4	661	l3 and pd<="2003"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/11/20 12:57
L5	0	l3 <="2003".pd.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/11/20 12:57
L6	6	l3 and triazol-\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/11/20 12:58